The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure.
Authors:
- 1 February 1989
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 27 (2) , 199-204
Abstract
1. The pharmacokinetics of the angiotensin converting enzyme inhibitor, lisinopril, were studied in an open, randomized, balanced, two‐period, crossover design in 12 in‐patients with stable, chronic congestive heart failure (CHF). 2. To evaluate the pharmacokinetics of lisinopril in CHF, lisinopril was administered orally (10 mg) and intravenously (5 mg) in each patient. Each dose was followed by a 72 h period with frequent blood sampling and fractional urine collections for radioimmunoassay of lisinopril. 3. Mean urinary recovery of lisinopril was 15 and 88% following oral and intravenous administration, respectively; absorption/bioavailability of lisinopril based on urinary recovery ratios was 16%, less than that found in normal subjects. 4. Serum concentrations of lisinopril following intravenous administration were higher in this study than those previously observed in normal subjects. 5. The results of this study suggest a reduced absorption of lisinopril in CHF and altered disposition, possibly associated with age as well as the disease state.Keywords
This publication has 12 references indexed in Scilit:
- A Comparison of Hypotensive Responses After Oral and Intravenous Administration of Enalapril and Lisinopril in Chronic Heart FailureJournal of Cardiovascular Pharmacology, 1987
- The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure.British Journal of Clinical Pharmacology, 1987
- Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failureAmerican Heart Journal, 1986
- Pharmacokinetics of repeated single oral doses of enalapril maleate (mk‐421) in normal volunteersBiopharmaceutics & Drug Disposition, 1984
- Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report.1984
- Estimation of an Effective Half-Life1984
- Enalapril maleate and a lysine analogue (MK‐521): disposition in man.British Journal of Clinical Pharmacology, 1982
- Bioavailability of quinidine in congestive heart failureBritish Journal of Clinical Pharmacology, 1981
- Corrections: The Two-Period Change-Over Design and Its Use in Clinical Trials1974
- The Two-Period Change-Over Design and Its Use in Clinical TrialsBiometrics, 1965